Acute Heart Failure Clinical Trial
— ECO/TOROfficial title:
Evaluation of Acute Cardiogenic Dyspnoea With Thorax Echography and Pro-BNP in the Emergency Department
Verified date | April 2014 |
Source | Comitato Etico di Area Vasta Sud Est |
Contact | n/a |
Is FDA regulated | No |
Health authority | Italy: The Italian Medicines Agency |
Study type | Observational |
LUNG ULTRASOUND IN THE MANAGEMENT OF DISPNEIC PATIENTS IN EMERGENCY DEPARTMENT
Introduction
This is a prospective randomized trial realized in the Emergency Department of the
University Hospital of Siena, Italy.
Dyspnea is one of the most common causes worldwide of admission to the Emergency Department
(ED) and acute heart failure (AHF) is a major cause of serious morbidity and death in such
population, above all in elderly patients. Incidence rate is significantly higher in men than
in women, in Europe it increases with age from 1.4/1000 person-years in subjects aged 55-59
years to 47.4/1000 person-years in those aged 90 years or older. The age-adjusted prevalence
of AHF in the United States averages 36 cases per 100,000 of the population and accounts for
10,000 deaths annually.
In clinical practice this symptomatology is usually investigated in the pre-hospital phase
only with history and physical examination; in the ED blood gas analysis (BGA), laboratory
tests and chest X-rays can be performed as primary exams. BNP and NT pro-BNP are now
considered reliable biochemical markers to distinguish cardiogenic from pulmonary etiology,
both for their diagnostic and prognostic value. On the other hand, these biomarkers are
affected by a "grey zone" of uncertainty, they are not available in all hospitals and their
dosage samples are expensive: thus we propose other tools to support the diagnostic process.
Status | Completed |
Enrollment | 0 |
Est. completion date | September 2013 |
Est. primary completion date | February 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: All the patients admitted to our Emergency Department from January 2011 to February 2013 with acute non-traumatic dyspnea. We included patients carried by ambulance and patients who came autonomously. Exclusion Criteria: - Age <18 years Post-traumatic dyspnea |
Time Perspective: Prospective
Country | Name | City | State |
---|---|---|---|
Italy | Azienda Ospedaliera Universitaria Senese | Siena |
Lead Sponsor | Collaborator |
---|---|
Comitato Etico di Area Vasta Sud Est |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Diagnostic Outcome (Reference Standard) | Since a uniform reference test is lacking for acute heart failure, we chose to use a consensus diagnosis as formal reference standard, in analogy with earlier studies and as recommended by recent diagnostic research guidelines. An independent panel of experts (made up of two cardiologists and one senior emergency physician) judged all the collected data for each patient to determine the final diagnosis. The panel of experts assessed acute heart failure diagnosis following the criteria and approach outlined by the ESC Heart Failure Guidelines. |
1 day | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02151383 -
Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure
|
Phase 2 | |
Completed |
NCT02135835 -
A Study to Evaluate the Efficacy and Safety of Shenfu Zhusheye in Patients With Acute Heart Failure
|
Phase 4 | |
Recruiting |
NCT05556044 -
Empagliflozin for New On-set Heart Failure Study Regardless of Ejection Fraction
|
Phase 3 | |
Recruiting |
NCT04363697 -
Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure -Thrombolysis in Myocardial Infarction 68 (DAPA ACT HF-TIMI 68)
|
Phase 4 | |
Completed |
NCT01193998 -
Impact of Validated Diagnostic Prediction Model of Acute Heart Failure in the Emergency Department
|
N/A | |
Not yet recruiting |
NCT01211886 -
Utility of Brain Natriuretic Peptide (BNP) in Patients With Type IV Cardio-renal Syndrome Admitted to the Intensive Care Unit (ICU)
|
N/A | |
Not yet recruiting |
NCT06465498 -
Investigating aCute heArt failuRe Decongestion Guided by Lung UltraSonography
|
N/A | |
Recruiting |
NCT05276219 -
Optimized Treatment of Pulmonary Edema or Congestion
|
Phase 4 | |
Recruiting |
NCT05392764 -
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03157219 -
Manipal Heart Failure Registry (MHFR)
|
N/A | |
Completed |
NCT06024889 -
Acute Effects of Furosemide on Hemodynamics and Pulmonary Congestion in Acute Decompensated Heart Failure.
|
Phase 1/Phase 2 | |
Terminated |
NCT04174794 -
Investigating Reduction of aCute heArt Failure Readmission With Lung UltraSound-preliminary Trial
|
||
Recruiting |
NCT05972746 -
Telemonitoring Program in the Vulnerable Phase After Hospitalization for Heart Failure
|
N/A | |
Enrolling by invitation |
NCT02258984 -
Can the Venus 1000 Help Clinicians Treat Patients With Severe Sepsis or Acute Heart Failure? The CVP Trial
|
N/A | |
Completed |
NCT02141607 -
Evolution of Molecular Biomarkers in Acute Heart Failure Induced by Shock
|
||
Completed |
NCT01870778 -
Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF
|
Phase 3 | |
Recruiting |
NCT05986773 -
Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance
|
Phase 4 | |
Recruiting |
NCT04163588 -
Sequential Nephron Blockade in Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03720288 -
Acetazolamide in Patients With Acute Heart Failure
|
Phase 3 | |
Recruiting |
NCT03717636 -
Early or Non-revoked in Hospital-day in Patients With Acute Heart Failure
|
N/A |